Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1996

View Archived Issues

New antihypertensive agents from Banyu

Distamycin analogues claimed by Mitsui Toatsu

New antitussive agent from Snow Brand Milk Products

Antiinflammatory glycolipid compounds from Nissin Food Products

Antiallergic/antiasthmatic compounds disclosed by Dainippon Ink

Eisai describes selective dopamine D3 antagonists

Novel anticancer agents from Sankyo

Toray reports peptides for toxic shock syndrome

British Biotech reports new MMP inhibitors

New ET-1 inhibitors from Ciba-Geigy

Scotia files EF27

University of Alberta discovers new chemokine-binding protein

Neurogen and Pfizer extend GABA-based collaboration

Affymax researches potential malaria vaccines

LXR Biotechnology/Boehringer Mannheim enter breast and prostate cancer collaboration

Oncor expands marketing of breast cancer test

SKB reports new vaccine compositions

Human growth hormone products recommended for approval

Advanced Polymer Systems to supply Johnson & Johnson with Microsponge-entrapped AHAs

New antisense compounds reported by French investigators

Alanex and Novo Nordisk expand diabetes research collaboration

MedImmune files IND for HPV vaccine candidate

New bile acid transporter inhibitors in preclinical testing at Searle

Acea describes candidate neuroprotectant

Glaxo Wellcome granted license to Cellegy orphan drug

Oncogene Science and Bayer initiate cancer diagnostics collaboration

CRC and Cortecs to develop cancer diagnostic tests

Terrapin Technologies obtains rights to Walter Reed compound library

Epic receives patent coverage for core drug delivery technology

Celox Laboratories' ViaStem receives patent coverage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...